Clinical recognition and aspects of the cerebral folate deficiency syndromes by RAMAEKERS, Vincent et al.
DOI 10.1515/cclm-2012-0543      Clin Chem Lab Med 2012; aop
 Review 
 Vincent  Ramaekers* ,  Jeffrey M.  Sequeira and  Edward V.  Quadros 
 Clinical recognition and aspects of the cerebral 
folate deficiency syndromes 
 Abstract:  We characterized cerebral folate deficiency 
(CFD) as any neuro-psychiatric condition associated with 
low spinal fluid (CSF) N 5 -methyltetrahydrofolate (MTHF) 
but normal folate status outside the central nervous system 
(CNS). The commonest cause underlying CFD syndromes 
is the presence of serum autoantibodies of the blocking 
type directed against folate receptor- α (FR α ) attached to 
the plasma-side of choroid plexus epithelial cells. Block-
ing FR antibodies inhibit MTHF transport across the cho-
roid plexus. Serum titers of FR antibodies may fluctuate 
significantly over time. Less frequent causes of CFD are 
FOLR-1 mutations, mitochondrial disorders and inborn 
errors affecting folate metabolism. Maternal FR antibod-
ies have been associated with neural tube defects while 
the presence of FR antibodies in either one or both parents 
increases the risk of an offspring with infantile autism. 
Recognizable CFD syndromes attributed to FR-antibod-
ies in childhood are infantile-onset CFD  presenting 4 – 6 
months after birth, infantile autism with neurological 
deficits, and a spastic ataxic syndrome from the age of 
1  year, while progressive dystonic or schizophrenic syn-
dromes develop during adolescence. FR autoantibodies 
are frequently found in autism spectrum disorders, in 
an Aicardi-Gouti è res variant and in Rett syndrome. The 
heterogeneous phenotype of CFD syndromes might be 
determined by different ages of onset and periods when 
FR autoantibodies are generated with consequent CNS 
folate deficiency. Folate deficiency during various critical 
stages of fetal and infantile development affects structural 
and functional refinement of the brain. Awareness of CFD 
syndromes should lead to early detection, diagnosis and 
improved prognosis of these potentially treatable group of 
autoimmune and genetically determined conditions. 
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 Introduction 
 Intestinal absorption of dietary folates, composed of folic 
acid (oxidized folate form) and its structurally derived 
folate compounds, is achieved by the concerted action of 
the folate receptor- α (FR α ; synonymous to FR-1; FOLR-1) 
and the proton-coupled folate transporter (PCFT) [ 1 – 4 ]. 
Folate uptake by cells and transport across the blood-
brain and the placental-fetal barriers involves the follow-
ing different mechanisms composed of specific proteins, 
being FR α -mediated endocytotic processes, the PCFT 
cooperating closely with FR proteins, the reduced folate 
carrier-1 (RBC-1) and the ATP-dependent folate exporter 
[ 5 ,  6 ]. FR α protein is a membrane-anchored protein and 
is characterized as a high-affinity low capacity folate 
transporter which can bind to very low folate concentra-
tions within the nanomolar physiologic range. FR α is 
expressed by specific epithelial cells and is responsible 
in cooperation with PCFT for folate passage across intesti-
nal,  placental-fetal epithelial barriers and across choroid 
plexus epithelial barriers to the spinal fluid compartment 
and from there across ependymal lining cells into neural 
tissues. The main folate transport to the central nervous 
system (CNS) occurs across the choroid plexus and is 
accomplished by FR α -mediated endocytosis and PCFT 
action. FR β (synonymous to FR β ; FR-2 or FOLR-2) is related 
to FR α and expressed by both mesenchymal-derived and 
epithelial cells. FR β expression has been demonstrated 
also in fetal epithelial cells, however, its functional con-
tribution to folate transport among human and murine 
species has not been resolved fully [ 5 – 7 ]. Another impor-
tant folate transporter across cell membranes is the low-
affinity, high capacity transporter known as the RFC-1, 
which is expressed in most cells. An ATP-dependent folate 
exporter is known to regulate intracellular folate concen-
trations ( Figure 1 ). 
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 Figure 1   Folate transport across epithelial barriers (upper part) and causes underlying CFD (lower part). 
Upper part of the Figure shows intestinal folate absorption and vectorial transport across the choroid plexus and ependyme using the 
ATP-dependent FR1-mediated endocytosis with PCFT, and eventually neuronal folate uptake and intracellular metabolism. Lower part of the 
Figure shows the three known causes of impaired folate transport across choroid epithelial cells: 1. The presence of blocking FR1 auto-
antibodies (shown by yellow arrows). 2. Mitochondrial dysfunction with reduced ATP generation needed by folylpolyglutamate  synthetase 
to attach glutamate residues to folate-monoglutamate for storage. 3. Genetic FOLR-1 defects predisposing to truncated FR1 protein with 
functional loss or  mistargetting of FR1 to membranes. DHF, dihydrofolate; DHFR, dihydrofolate reductase; F, folates; F-, folylpolyglutamate; 
FPGS, folylpolyglutamate synthase; FR1, folate receptor- α ; GGH,  γ -glutamate hydrolase representing the lysosomal enzyme for folylpolyglu-
tamate breakdown to monoglutamate; PCFT, proton-coupled folate transporter; RBC, red blood cells; RFC, reduced folate carrier-1. 
 N 5 -Methyl-tetrahydrofolate (MTHF) is the predominant 
and physiological methyl-group carrying folate form in 
plasma and the folate form known to cross the blood-CSF 
barrier to enter the spinal fluid compartment and from there 
through a second ependymal-lining barrier into the neural 
tissues. MTHF transfer across the choroid plexus is an active 
vectorial transport mechanism resulting in at least 1.5-
fold higher CSF concentrations compared to plasma levels 
( Figure 1 ). MTHF transport across the choroid plexus is medi-
ated by FR α anchored to plasma-facing basal membranes of 
choroid epithelial cells [ 5 ,  6 ,  8 ,  9 ]. After MTHF binding by 
FR proteins and cellular uptake by choroid epithelial cells 
through an endocytotic process, MTHF is released from its 
FR protein through interaction with the PCFT [ 1 ]. This is fol-
lowed by MTHF delivery into the spinal fluid compartment 
from where MTHF is taken up by ependymal lining cells to 
be delivered into neural tissues. 
 After folate uptake by neurons, only a minor portion 
of assimilated folate participates in different cellular 
meta bolic functions, while the major portion will be 
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stored as polyglutamate folate forms within the cyto-
plasm and mitochondria after attachment of multiple 
glutamate residues by the ATP-dependent enzyme folyl-
polyglutamate synthetase. Brain folate reserves have 
been estimated to remain adequately replete for a period 
of about 100 days. FR α is highly expressed in reproduc-
tive tissues and plays a major role in providing folate to 
the embryo and fetus. 
 The various reduced folate forms serve as essential 
co-factors in many metabolic processes [ 8 ]. After intesti-
nal uptake, folic acid is reduced by the enzyme dihydro-
folate reductase (DHFR) and part of this will be methyl-
ated to MTHF. In the brain, expression of DHFR enzyme is 
extremely low in humans so that the brain depends on the 
daily transport of MTHF and other reduced folate forms 
( Figure 2 ). Among many metabolic functions, MTHF is 
needed as substrate for the conversion of homocysteine 
to methionine by the B12-dependent enzyme methionine 
synthase. Through this latter enzymatic homocysteine 
degradation, MTHF transfers it s methyl-group to methio-
nine which enters into the adenosyl cycle and will be 
converted to the activated methyl-group donor S-aden-
osyl-methionine (SAM), used in over 100 methylation 
reactions. The resulting product tetrahydrofolate (THF) 
is recycled again to MTHF after recharging with methyl-
groups originating from serine-glycine interconversion. 
Another folate form 10-formyl-THF is necessary for de 
novo purine synthesis, while 5,10-methylene-THF partici-
pates in the de novo thymidine synthesis. Thus DNA rep-
lication and formation of RNA transcripts needed for cell 
proliferation and maturation of the developing nervous 
system depends on an adequate pool of various reduced 
folate forms. 
 Moreover, epigenetic control of neuronal gene 
expression and transcription repression of other genes 
is indirectly linked to MTHF as SAM is the substrate for 
DNA-methyltransferase-I which enzymatically transfers a 
methyl-group to the CpG islands and thereby methylates 
gene promoter regions in order to initiate the process of 
gene transcription repression. 
 In neurologically handicapped patients, CSF meas-
urements have detected low MTHF values while plasma 
and red blood cell folate, homocysteine and vitamin B12 
levels were normal. This group of neurological disorders 
can be defined as the Cerebral Folate Deficiency (CFD) 
syndromes and represent different clinical phenotypes 
[ 10 ,  11 ]. The most common cause of CFD identified thus 
far, is the presence in serum of circulating folate receptor 
(FR) autoantibodies that cross react with soluble FR found 
in animal-derived milk (bovine, goat or camel milk), 
which has high structural homology with the human FR 
antigen [ 12 ,  13 ]. Less frequent causes of CFD are mitochon-
drial disorders and abnormalities of the  FOLR-1 gene [ 7 , 




































 Figure 2   Pathways of folate transport and metabolism. 
 B2, riboflavine; B6, pyridoxine; B12, cobalamine and methyl-cobalamin; BH4, tetrahydrobiopterine; CSF, cerebrospinal fluid; DHF, dihydro-
folate; DHFR, dihydrofolate reductase; FR, folate receptor; Gly, glycine; MS, methionine synthase; MTHFR, 5,10-methylene-tetrahydrofolate 
reductase; Ser, serine; THF, tetrahydrofolate. 
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new emerging group of disorders, its diagnosis and dif-
ferential diagnosis, diagnostic guidelines and therapeutic 
strategies as well as new findings about these FR autoanti-
bodies. We also discuss the possible reasons for the emer-
gence of different clinical phenotypes at different ages. 
 History and epidemiology 
 The first patients with the infantile-onset CFD associated 
with low CSF folate levels were reported by us in 2002 [ 10 ]. 
Infantile-onset CFD syndrome shows an equal gender dis-
tribution, affects all ethnic groups with an estimated prev-
alence between 1/4000 and 1/6000 children. However, 
infantile-onset CFD and other CFD syndromes are likely 
to be underdiagnosed. After a  FOLR-1 gene defect was 
initially excluded, further investigation revealed that the 
most likely etiology of infantile CFD was the presence of 
postnatally acquired FR autoantibodies of the blocking 
type in the serum of these patients. FR autoantibodies had 
been discovered earlier by our colleagues at the State Uni-
versity of New York in the serum of mothers who had given 
birth to a child with a neural tube defect (NTD) [ 15 ]. 
 Further testing for blocking FR autoantibodies in 
various populations indicated that as we age the immune 
system also changes leading to immunosenescence. 
We found a prevalence of blocking FR autoantibodies 
from  < 2% in the under 16 years age group increasing to a 
prevalence estimated in healthy adult women at 4% – 7% in 
Spain [ 16 ], 9% – 13% in Ireland [ 17 ] and 10% – 15% in the US 
population [ 15 ]. A low titer of this antibody in a fraction of 
the adult population appears to be non-pathologic. Post-
natally acquired FR autoantibodies blocking folate trans-
port to the brain have been associated with the infantile-
onset cerebral folate deficiency syndrome [ 12 ], which in a 
number of patients manifests as low-functioning autism 
with neurological deficits. Thereafter, several studies 
associated serum FR antibodies with Rett syndrome and a 
variant of the Aicardi-Gouti è res syndrome. Mitochondrial 
encephalopathies have in a number of cases been asso-
ciated with CFD because vectorial folate transport across 
the blood-brain barrier depends on adequate ATP produc-
tion. The first reported  FOLR-1 gene defects have only been 
recently identified, but the exact prevalence of genetic 
defects remains to be determined. 
 FR autoantibody assay 
 The two types of antibodies identified in serum of patients 
are: blocking antibody and binding antibody. The two 
antibodies can be measured by specific assays described 
and exert their pathological effects either by functional 
blocking of folate transport or by disrupting the FR by an 
antigen-antibody mediated inflammatory response. We 
have identified both IgG and IgM autoantibodies in these 
conditions [ 15 – 17 ]. 
 Assay for blocking autoantibodies to FR α 
 Testing for blocking autoantibodies against FR is per-
formed by measuring the blocking of radiolabeled folic 
acid binding to a known amount of purified FR α from 
human milk as previously described [ 15 ,  16 ]. Blocking 
autoantibodies prevent the binding of [3H]folic acid to 
FR and the autoantibody titer is expressed as pmol FR 
blocked/mL of serum. The blocking antibodies could be 
either IgG or IgM and this method does not identify any 
specific antibody type. 
 Assay for binding autoantibodies to FR α 
 An ELISA-based measurement is used to determine the 
presence of IgG immunoglobulins that bind to epitopes 
on purified apo FR α from human milk as previously 
described [ 17 ]. The assay only identifies IgG autoantibod-
ies of either the blocking or binding type and does not 
identify IgM antibodies. 
 Cerebral folate deficiency 
syndromes associated with FR 
autoantibodies ( Figure 3 ) 
 The clinical syndromes of CFD attributed to FR autoanti-
bodies can be found from the prenatal period into adult-
hood. The different clinical phenotypes are speculated to 
be determined by the presence of maternal FR antibodies 
during pregnancy and/or the specific postnatal age at 
which these FR autoantibodies occur to impair CNS folate 
transfer. 
 The first paper on FR autoantibodies reported their 
presence in the serum of mothers with a history of neural 
tube defect (NTD) pregnancy [ 15 ]. These FR antibodies 
directed against the FR α at the placental-fetal barrier 
could reduce folate transfer resulting in embryonic folate 
deficiency that affected the normal process of neural tube 
closure. No consistent data described a link between the 
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presence of serum FR antibodies in pregnant mothers 
and the origin of other embryonic or fetal malformations. 
However, a recent paper by us demonstrated an associa-
tion between the presence of FR antibodies in one or both 
parents having a child with infantile autism [ 18 ]. The latter 
finding suggested that prenatal folate depletion due to FR 
autoimmunity in the mother interferes with brain devel-
opment and predisposes to autism. FR antibodies in the 
fathers are speculated to induce epigenetic DNA changes of 
their transmitted genome, predisposing to autism in their 
children. The essential role of adequate periconceptional 
folate levels among mothers has been shown to reduce the 
risk of NTD pregnancy or having a child with autism [ 19 ]. 
 The first report on CFD syndrome was recognized 
and described among five patients in 2002 [ 10 ], and was 
later named infantile-onset CFD syndrome which mani-
fests 4 – 6 months after birth and is characterized by the 
sequential occurrence of more than three out of seven 
major clinical criteria ( Figure 4 ) [ 11 ], based on clinical 
findings among 20 patients. The difficulty in establishing 
an early diagnosis is the fact that the full-blown clinical 
picture does not manifest until the age of 2 ½ years. For 
this reason a high index of suspicion and good knowledge 
of early symptoms and signs of infantile-onset CFD is 
required to establish a tentative diagnosis and start treat-
ment as soon as possible. 
Birth
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-FOLR-1 and FOLR-2 mutants ?
 Figure 3   Life tree depicting the recognized CFD syndromes attributed to FR autoimmunity according to age. 
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 Figure 4   Time sequence of clinical features of the infantile-onset CFD syndrome. 
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 In undiagnosed cases, visual disturbances start to 
manifest from the age of 3 years followed by progressive 
visual loss, while progressive hearing loss occurs from the 
age of 6 years. 
 After excluding  FOLR-1 and  FOLR-2 gene defects in the 
majority of cases, we found serum containing FR autoanti-
bodies of the blocking type [ 12 ]. In 55 patients tested, there 
was an inverse correlation between the autoantibody titer 
and the CSF folate levels ( Figure 5 ) [ 13 ]. Antibodies are 
absent in mothers of children with infantile CFD attrib-
uted to FR autoantibodies. Several families are known to 
us where two or more siblings are affected by this condi-
tion, and investigation of six consanguineous families 
where parents were first-line cousins did not reveal a 
single monogenetic origin, and therefore, a multigenetic 
origin is likely for infantile-onset CFD associated with FR 
autoimmunity (unpublished findings). 
 In about half of the patients suffering from infantile-
onset CFD syndrome due to FR autoimmunity, the brain 
MRI showed moderate fronto-temporal atrophy with signs 
of delayed myelination or later signs of periventricular 
and subcortical demyelination manifesting from the age 
of 18 months. In three children, slowly progressive supra- 
and infratentorial atrophy was noted [ 11 ]. 
 As visual disturbances manifest from the age of 3 
years, visual evoked potentials after flash stimuli begin 
to show prolonged latencies followed by reduction and 
extinction of P2 – wave amplitudes. Progressive sensori-
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 Figure 5   Correlation between blocking FR autoantibody titer and 
CSF MTHF level in 55 patients with cerebral folate deficiency (open 
circles). 
 Filled circles represent non-CFD patients with normal levels of folate 
in CSF who tested negative for the autoantibody (reprinted from Dev 
Med Child Neurol). 
6 years. Nerve conduction studies were found to be com-
pletely normal. Somatosensory evoked responses after 
tibial nerve stimulation may show either no response or 
prolonged latencies. 
 The second recognized CFD syndrome is a spastic-
ataxic phenotype and presents after the age of 1 year, 
while neurodevelopment during the first year of life is 
normal and features of the infantile-onset syndrome are 
not found. In contrast to the moderate to severe mental 
retardation observed in the infantile-onset syndrome, 
cognitive functions in the spastic ataxic syndrome remain 
preserved [ 20 ]. Neuro-imaging of the brain and spinal 
cord were normal. Visual evoked potentials may show 
prolonged latencies. Autosomal recessive spastic paraple-
gia and spastic ataxia syndromes need to be excluded. 
 The third recognized CFD syndrome is infantile 
autism, frequently associated with three or more neuro-
logical deficits encountered in the infantile-onset CFD 
[ 21 ], but infantile autism without neurological deficits 
has been increasingly recognized [ 22 ]. In a group of 25 
patients with infantile autism associated with neurologi-
cal deficits, spinal fluid MTHF levels were lowered due to 
relatively high blocking serum FR autoantibody titers in 
almost all (24 of 25) patients. MRI of the brain and spinal 
cord was normal in most cases. However, in 49 patients 
affected only by infantile autism without neurological 
deficits and normal neuro-imaging, a lower proportion of 
15 out of 49 patients had spinal fluid MTHF values slightly 
or moderately below the reference range among healthy 
controls and was statistically not significant. In the latter 
group of infantile autism patients serum blocking FR 
auto-antibodies were positive in about half the patients 
(51%) but the mean titer was much lower compared to 
the group of infantile autism with neurologic abnormali-
ties ( Figure 6 ). These results suggested that the advent of 
additional neurological abnormalities in autism will be 
induced by lower folate levels within the nervous system. 
A recent study showed either blocking and/or binding FR 
autoantibodies in 75% of 93 tested patients with autism 
spectrum disorders, but CSF folate was not measured con-
sistently among all patients [ 22 ]. 
 Postnatal development of FR autoantibodies has been 
associated with all other phenotypes belonging to the 
autism spectrum disorders like Rett syndrome, PDD-NOS, 
childhood disintegrative disorder and Asperger syndrome 
[ 10 – 12 ,  23 ,  24 ]. 
 A new CFD syndrome has been recognized among five 
patients presenting from adolescence to adulthood. Dysto-
nia at onset was localized and during its course extended 
to generalized dystonia with subsequent development of 
bradykinesia and a pyramidal syndrome. Inconsistent 
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of their MECP-2 genotype, 14 out of 33 Rett patients (42%) 
from Germany, Spain and Portugal were found to have 
lowered CSF MTHF levels. In the 14 Rett patients with 
lowered CSF folate, the presence of serum blocking FR 
antibodies could explain disturbed folate transport to 
the brain in eight of the patients resulting in a low CSF/
serum folate ratio. However, in six Rett patients with low 
CSF folate, FR antibody testing was negative and the CSF/
serum folate remained normal so that an increased folate 
turnover was suspected to result from increased utiliza-
tion or catabolism [ 23 ]. 
 One important observation from these studies was 
that in the clinical Rett phenotype without known genetic 
defects (MECP-2, CDKL5, FOXG1) a search for CFD and FR 
autoimmunity should be initiated. Our findings suggested 
a correlation of milk consumption with the presence of 
these FR antibodies in Rett syndrome [ 23 ]. 
 CFD associated with mitochondrial 
disorders and  FOLR-1 gene defects 
 Much rarer underlying causes of CFD are mitochondrial 
disorders, mitochondrial DNA depletion syndrome (Alpers 
type), Kearns-Sayre syndrome and genetic anomalies of 
the  FOLR-1 gene [ 7 ,  14 ,  29 – 34 ]. 
 Patients affected by  FOLR-1 gene mutations exhibit 
a strikingly similar clinical phenotype to that observed 
in CFD due to FR α autoantibodies. With the exception 
of a single patient, all suffered from frequent epilep-
tic seizures [ 7 ,  34 ,  35 ]. All children with reported FOLR-1 
mutations had very low CSF MTHF concentrations below 
10 n M and needed much higher folinic acid doses for treat-
ment. Molecular characterization of  FOLR-1 gene abnor-
malities identified on both alleles nonsense and missense 
mutations, a duplication in one patient and one splicing 
error in one patient, all of which lead to functional loss 
of FOLR-1 protein due to either protein instability, reduced 
membrane expression of truncated FOLR-1 proteins, or 
mistargetting of mutated FOLR-1 proteins [ 33 ]. None of 
the reported patients had signs of embryonic malforma-
tions or neural tube defects. This raises the question as 
to why these FOLR-1 mutations did not have any effect on 
embryonic and fetal development. Alternate mechanisms 
operating for folate transport in vivo to provide adequate 
maternal folate to the fetus is a potential explanation. 
 Previous gene knock-out experiments in mice had 
shown that nullizygous FOLR-1 pups had severe embry-
onic malformations or died in utero, while nullizygous 



























































 Figure 6   Comparison of spinal fluid MTHF levels (mean ± SD 
expressed as nM/L) and serum blocking FR autoantibod-
ies (mean ± SD expressed as picomol FR blocked/mL serum) 
between patients with autism associated with neurological 
deficits (ND), infantile autism and healthy age-matched controls. 
autism + ND, autism associated with neurological deficits; MTHF, 
methyl-tetrahydrofolate. 
features included slight cognitive dysfunction, gait ataxia 
and a history of seizures. The two oldest patients became 
severely disabled. CT brain scans in two patients (age 32 
and 50 years) showed diffuse brain calcifications suggest-
ing Fahr ’ s syndrome. Blocking FR autoantibodies were 
found in all patients associated with low CSF MTHF levels 
(unpublished case series). 
 A case of CFD syndrome associated with blocking FR 
autoantibodies presenting from the age of 11 years as cata-
tonic schizophrenia has been reported [ 25 ]. These findings 
have been confirmed in at least six of our own patients suf-
fering from chronic schizophrenia (unpublished cases). 
 Finally, one single case of a 58-year-old adult with 
dementia and myoclonus has been reported to suffer from 
CFD due to FR autoantibodies who recovered dramatically 
after successful folinic acid supplements [ 26 ]. 
 Secondary CFD syndromes with the presence of FR 
autoantibodies in a variable number of cases have been 
described and comprise Rett syndrome and variants of 
the Aicardi-Gouti è res syndrome [ 23 ,  27 ,  28 ]. Irrespective 
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the predominant role of FOLR-1 in providing adequate 
folate to the embryo in the mouse. 
 De Marco provided evidence for genetic asso-
ciations between molecular variations of the  FOLR-1 
gene and NTD in humans [ 36 ]. In addition, immuno-
histochemical and mRNA studies have confirmed the 
expression of FOLR-1, PCFT and the RFC-1 at the human 
 placental-fetal barrier during the first trimester of preg-
nancy and at term where their concerted action is neces-
sary to  maintain vectorial folate transport to the embryo 
and fetus [ 6 ]. 
 To explain the absence of embryonic malformations 
and late-onset of clinical features beyond 2 years among 
their patients with  FOLR-1 gene mutations, Steinfeld et al. 
suggested that folate transport in humans may differ from 
that in the mouse and that FOLR-2 may play a role in trans-
porting folate to the fetus. 
 It was suggested that FOLR-2 expression in utero and 
during the first postnatal 2 years among subjects with 
FOLR-1 homozygous mutations provided sufficient com-
pensatory protection against folate depletion [ 7 ]. 
 However, such speculation by Steinfeld et al. has not 
been substantiated with experimental data. 
 Finally, one report described low spinal fluid MTHF 
levels and improvement after folinic acid intramuscularly 
in a child suffering from the H-ABC syndrome, or better 
known as Hypomyelination with Atrophy of the Basal 
Ganglia and Cerebellum. The serum was not analyzed for 
the presence of FR antibodies [ 37 ]. 
 Diagnostic investigations 
and  differential diagnosis 
 In the diagnostic work-up process of a suspected CFD 
syndrome, we strongly recommend all diagnostic guide-
lines as outlined in  Table 1 to be performed. Moreover, 
causes of systemic folate deficiency and the use of anti-
folate drugs should be considered and excluded in each 
patient [ 38 ] (Table 2). 
 If on the basis of history, clinical examination and 
additional investigations the patient may suffer from 
one of the aforementioned CFD syndromes, a lumbar 
puncture is necessary to measure MTHF meta bolites in 
addition to the determination of serum FR  antibodies 
of the blocking and binding type. After finding low CSF 
MTHF values, the most common underlying cause of 
CFD  syndrome are FR antibodies of the blocking type 
which are able to inhibit the binding site for MTHF and 
prevent its transfer across the choroid plexus to the 
CNS [ 12 ]. In  the infantile-onset CFD syndrome blocking 
FR antibodies belong to the IgG1, IgG3 or IgG4 isotype 
while  often combinations of the IgG1 with IgG3 or the 
IgG1 with IgG4 antibodies are encountered in the same 
individual [ 13 ]. 
 In addition, among patients suffering from autism 
spectrum disorders, FR antibodies of the binding type 
have been found and are thought to form complexes with 
FR antigen at the blood-brain barrier followed by comple-
ment binding with loss of function of FR mediated folate 
uptake and transport capacity across the blood-brain bar-
riers. Spinal fluid examination did not show the presence 
of intrathecal FR antibodies of the blocking or binding 
type in any of the CFD syndromes [ 12 ,  22 ]. 
 The differential diagnosis of the infantile-onset CFD 
syndrome includes a number of conditions character-
ized by a combination of similar features like irritability 
and insomnia, deceleration of head growth with micro-
cephaly, psychomotor retardation and regression, hypo-
tonia and ataxia, pyramidal deficits, dyskinesias and 
epilepsy. 
 One of the conditions most closely resembling the 
infantile-onset CFD syndrome is Rett syndrome in girls. 
The differential diagnosis should consider also neuro-
muscular disorders, mitochondrial encephalopathies of 
early onset, the congenital syndrome of protein glycosyla-
tion type Ia, disorders of pterin metabolism, infantile neu-
ronal ceroid lipofuscinosis type 1, arigininemia, Menkes 
disease and some neurogenetic syndromes like the Allan-
Herndon-Dudley syndrome, Marineso-Sj ö gren syndrome, 
Pelizaeus-Merzbacher syndrome and an X-linked oli-
gophrenin 1 gene defect. Further investigations including 
neurophysiologic studies, neuro-imaging and appropriate 
laboratory testing as indicated in  Table 1 can help to dis-
tinguish these disorders. 
 One pitfall in the diagnosis of these FR autoimmune 
mediated CFD syndromes is the finding of serum nega-
tive for FR antibodies even if a lumbar puncture shows 
lowered MTHF values in spinal fluid. The reason may lie 
in the large fluctuations in FR antibody titer observed 
over time which may show one or two peaks of high titers 
alternating with low or even absent FR antibodies during 
an interval of 6 weeks (Figure 7). However, the presence 
of an inversion of the normal CSF to serum MTHF ratio 
(normal   ≥  1.5) may indicate that blocking FR antibodies 
have been complexed to FR α sites on the choroid epi-
thelial cells after clearance of circulating FR antibodies 
from serum. The fluctuating patterns of FR antibodies 
over time have been demonstrated now for infantile-onset 
CFD, infantile autism with neurological deficits and infan-
tile autism spectrum disorders. After intervention with a 
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 Full ophthalmologic and auditory examination 
 Neuro-imaging 
 Electrophysiology (EEG, evoked potentials; if necessary EMG and nerve conduction studies) 
 Laboratory investigations 
 Hematology and red blood cell (RBC) indices 
 Serum and RBC folate, homocysteine, amino acids (tryptophane, phenylalanine, serine, glycine, arginine) 
 Serum N 5 -methyl-tetrahydrofolate (MTHF) 
 Leucocyte or fibroblast enzyme activity for Methylene-tetrahydrofolate reductase 
 Plasma lactate, pyruvate, ammonia and glucose 
 Serum copper and ceruloplasmin 
 Serum CK levels 
 Plasma TSH and T3, T4 levels 
 Serum gliadin antibodies 
 Exclude vitamin B2, B6 and B12 deficiencies 
 Spinal tap for CSF 
  Glucose, lactate, pyruvate 
  CSF MTHF, pterins and biogenic mono-amines 
  Amino acids (tryptophan, serine, glycine) 
 Determination of CSF: serum MTHF ratio (normal ratio being   ≥  1.5) 
 Serum FOLR-1 antibodies of the blocking and binding type 
 Genetic analysis of the FOLR-1 gene (consider PCFT analysis based on clinical phenotype) 
 Consider MECP2 mutation for Rett syndrome (or mutations of CDKL5 and FOXG1 genes) 
 In case of megaloblastic anemia: 
   –  Consider DHFR gene alterations 
   –  Consider PCFT mutations (congenital folate malabsorption) 
 In case of low HVA, 5HIAA, elevated L-dopa and 5-OH-tryptophane: 
   –  Consider aromatic amino acid decarboxylase deficiency 
 In case of high phenylalanine, low HVA, 5HIAA, MTHF and elevation of neopterin, dihydrobiopterin and low tetrahydrobiopterin:
  –  Consider dihydropteridin reductase deficiency 
 In selected instances: 
   –  Sialotransferrin analysis in plasma (CDG Ia syndrome) 
   –  Urinary amino- and organic acids (mevalonic aciduria) 
   –  Urinary screening for purine- and pyrimidine disorders (adenylosuccinase deficiency, dihydropyrimidine dehydrogenase deficiency) 
 Table 1   Guidelines of diagnostic and differential diagnostic investigations for CFD. 
milk-free diet, FR antibodies showed significant down-
regulation over time in most CFD patients. 
 Two autosomal recessively transmitted inborn errors 
of metabolism frequently associated with secondary 
CSF MTHF depletion are due to deficient enzyme activ-
ity of aromatic amino acid decarboxylase [ 39 ] and dihy-
dropteridine reductase deficiency [ 40 ,  41 ]. Simultaneous 
CSF measurement of mono-amine metabolites (L-Dopa, 
3-O-methyl-dopa, homovanilic acid, 5-hydroxy-tryp-
tophan and 5-hydroxy-indole acetic acid) and pterine 
metabolites show typical abnormal profiles for each of 
these two disorders. A third disorder of de novo serine 
synthesis, due to D-glycerate dehydrogenase deficiency, is 
associated with brain serine deficiency with consequent 
MTHF deficiency in spinal fluid because serine serves as a 
one-carbon pool donor in the CNS necessary for re-meth-
ylation of THF to MTHF [ 42 ]. 
 With the finding of megaloblastic anemia or pan-
cytopenia and homocysteinemia, plasma and red 
cell  MTHF should be determined and inborn errors of 
folate metabolism should be excluded such as congeni-
tal folate malabsorption due to genetic defects of the 
PCFT, MTHFR reductase deficiency and DHFR deficiency 
[ 1 ,  43 – 45 ]. The latter group of genetic folate disorders 
cannot be classified as CFD syndromes since plasma 
and red blood cell folate metabolite profiles will be low 
with aberrant folate form profiles. Therefore, MTHF 
metabolites should be quantified in serum for which 
age-dependent reference values in normal  children have 
been established [ 46 ]. 
 MR spectroscopic findings in CFD 
syndromes 
 MR spectroscopy in CFD associated with FR autoan-
tibodies may show loss of choline and inositol peaks 
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within the white matter. Similar MR spectroscopy 
studies among CFD patients associated with FOLR-1 
mutations and very low MTHF levels, could also confirm 
hypomyelination with low choline and inositol peaks 
of white matter particularly within parieto-occipital 
regions [ 7 ]. 
 If the rate of methyl-transfer pathways in CFD syn-
dromes diminishes, normal compactness and stability of 
myelin becomes compromised through failure of methyl-
transfer to arginine at position 107 of myelin-basic protein 
(MBP), one of its major proteins. Myelin containing 
unmethylated MBP is less stable and compact compared 
 Classification of condition  Underlying mechanism 
 Prenatal folate deficiency  
  Neural tube defects  Maternal and embryonic folate deficiency 
  Maternal FR autoantibodies blocking placental folate transfer 
  Autism spectrum disorders  Maternal FR autoantibodies during pregnancy 
  Paternal FR autoantibodies 
  Low dietary folate intake 3 months before and after conception 
 Systemic folate depletion  
  Malnutrition  Folate deficient in the diet or food deprivation 
  Malabsorption  Reduced folate absorption in the jejenum 
   Celiac disease  Gluten enteropathy 
   Chron and jejunal diseases  Affects folate absorption 
  Antifolate agents  
   Chemotherapy (MTX)  Blocks RFC1 carrier; inhibits dihydrofolate reductase 
   Isoniazide  Tuberculostatic drug 
   Sulfonamides  Analogs of para-aminobenzoic acid, interfering with THF synthesis in sensitive 
bacteria 
   Anticonvulsant drugs  Interfering with cellular folate uptake 
   Carbidopa  Inhibits aromatic amino acid decarboxylase with consequent SAM and 5MTHF 
overconsumption 
  Congenital folate malabsorption  Hereditary factor involving the PCFT gene 
  Systemic inborn errors of folate metabolism  
   MTHFR deficiency  Depletion of enzymatic product 5MTHF 
   Dihydrofolate reductase deficiency  Defective conversion of folic acid or DHF to THF 
   Formiminotransferase deficiency  Defective histidine derived one-carbon transfer to THF 
 Cerebral folate deficiency  
  Infantile-onset CFD  Serum FR autoantibodies 
  Low-IQ autism with neurological deficits  Serum FR autoantibodies 
  Late-onset spastic-ataxic CFD syndrome  Serum FR autoantibodies 
  Autism spectrum disorders  Serum FR autoantibodies 
  Dystonia  Serum FR autoantibodies 
  Catatonic schizophrenia  Serum FR autoantibodies 
  Dementia and myoclonus  Serum FR autoantibodies 
  One-carbon pool deficiencies in the CNS  
   3-Phosphoglycerate dehydrogenase deficiency  Defective serine synthesis affecting one-carbon donor pool 
  Inborn errors mainly affecting brain folate metabolism  
   CFD with FOLR-1 mutations on both alleles  Loss of FOLR-1 function 
   Dihydropteridine reductase deficiency  Unknown mechanism of secondary CFD 
   Aromatic L-amino acid decarboxylase deficiency  Overconsumption of 5MTHF and SAM 
  Mitochondrial DNA depletion syndrome (Alpers type)  DNA polymerase gamma (POLG-1) gene mutations a 
  Kearns-Sayre syndrome  Disturbed active folate transport at choroid plexus and  ↓ storage a 
  Mitochondrial encephalopathies  Disturbed active folate transport at choroid plexus and  ↓ storage a 
  Rett syndrome  Variable proportion with CFD and FR autoantibodies 
  ( ± MECP-2 defect) 
  Variant of Aicardi-Goutieres syndrome  Variable proportion with CFD 
  Hypomyelination with Atrophy of the  CFD of unknown cause 
  Basal Ganglia and Cerebellum (H-ABC) Syndrome  
 Table 2   Overview of systemic folate depletion and conditions of CFD associated with low spinal fluid MTHF levels. 
 a Suspected reduced activity of ATP-dependent folylpolyglutamate synthase resulting in failure of folate storage. 
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to myelin with methylated MBP due to cationic charge 
differences at the arginine 107 position. Using SAM as 
substrate, the addition of one or two methyl groups to 
arginine residues in position 107 of MBP is catalyzed by 
the MBP-specific protein methylase 1 (SAM: protein-argi-
nine N-methyltransferase, EC 2.1.1.230). Consequently, 
myelin destabilization due to cationic charge alterations 
of unmethylated MBP molecules explains the inability to 
form compact myelin sheaths [ 47 ]. This explains delayed 
progression of myelination and later-onset of myelin dis-
integration in CFD syndromes as confirmed by brain MRI 
sequences at different ages and histopathological changes 
described as subacute combined degeneration of lateral, 
posterior and anterior columns within the spinal cord [ 48 ]. 
 One hypothesis explaining the loss of choline in 
white matter and spinal fluid suggested that in the case 
of CNS folate deficiency the reduced methyl-transfer 
processes leading to homocysteine degradation and 
production of the universal methyl-donor SAM are 
replaced by alternative metabolic pathways mobilizing 
choline from white matter and neuronal cell membranes 
containing phosphatidyl-choline and inositol. The liber-
ated choline will be oxidized in two steps to betaine (i.e., 
tri-methyl-glycine) which is used by the enzyme betaine-
homocysteine S-methyltransferase for homocysteine 
conversion to methionine and subsequent production of 
the universal methyl-donor SAM. The consequent higher 
choline consumption due to CNS folate deficiency will 
deplete physiologic choline reserves and perturb normal 
choline metabolism essential for neurodevelopment, 
since choline and its derivatives serve as components 
of structural lipoproteins, membrane lipids and as a 
precursor of the neurotransmitter acetylcholine. Folinic 
acid supplementation has resulted in remyelination and 
reversal of choline and inositol peaks to normal on MR 
spectroscopy [ 7 ]. 
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 Figure 7   Fluctuating FR autoantibodies of the blocking type in children with infantile-onset CFD syndrome and infantile autism associated 
with neurological deficits. 
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 Therapeutic strategies 
 After identification of FR antibodies, the treatment of 
choice is the administration of high doses folinic acid 
according to a previously described protocol [ 11 ,  38 ]. In 
treated patients a second spinal tap after 6 – 12 months 
could show normalization of MTHF levels in CSF. Treat-
ment is started at a daily dose of 0.5 – 1 mg/kg body weight, 
divided into two equal dosages. Depending on the clinical 
response, daily doses could be titrated up to 2 – 3 mg/kg/
day. If therapeutic folinic acid intervention fails to show a 
positive response after 6 months, MTHF should be meas-
ured again in CSF in order to adapt the folinic acid dose. 
 In children having CFD due to FOLR-1 mutations 
higher folinic acid doses up to 3 – 5 mg/kg/day were neces-
sary to improve outcome and correct CSF MTHF levels [ 7 ]. 
 The use of these high oral folinic acid doses will 
increase serum MTHF values significantly so that the low-
affinity high capacity folate transporter, i.e., the RBC1 will 
be able to transport folinic acid and any MTHF formed, 
across the blood-CSF barrier and circumvent blocked FR α 
passage due to FR antibodies or FOLR-1 mutations with 
loss of function [ 11 ]. 
 An animal milk-free diet has been shown to downreg-
ulate the FR autoantibody titers [ 13 ]. 
 The effect of a milk-free diet can be explained by the 
high molecular mimicry between its soluble FR antigen 
and the human FR α antigen to which specific serum FR 
antibodies are generated. The serum FR antibodies have 
shown higher affinity for the soluble FR antigens con-
tained in animal milk  – like bovine, goat and camel milk. 
For this reason we speculate that exposure to soluble FR 
antigen from animal milk triggers the immune response 
within the gut to generate specific FR antibodies in geneti-
cally predisposed individuals. These FR antibodies formed 
against soluble milk-derived FR antigen, cross-react with 
the human FR α antigen exposed at the plasma-side of 
choroid epithelial cells at the blood-CSF barrier and 
other epithelial surfaces such as the reproductive system. 
New trials using intravenous immunoglobulins, steroids 
and immunosuppressive drugs still await further critical 
assessment. 
 Outcome 
 As soon as the diagnosis of a specific CFD syndrome has 
been confirmed by appropriate investigations (CSF analy-
sis and serum FR autoantibodies), treatment should be 
started as soon as possible, because the longer the interval 
between onset of first clinical signs and symptoms and 
start of the therapy, the poorer the prognosis will be. In 
three children with unexplained irritability, hypotonia 
and motor delay and infantile-onset of seizures in two of 
these infants, low CSF folate or serum FR antibodies were 
identified prior to the age of 1 year. This was followed by 
prompt intervention with folinic acid. Follow-up of these 
children could demonstrate full clinical recovery with full 
seizure-control and lack of any neurocognitive deficits in 
later years. Diagnosis and folinic acid treatment beyond 
the age of 1 year, will increase the risk of neurologic defi-
cits and mental retardation. 
 Conclusions 
 Early detection and treatment of FR autoimmunity is 
expected to prevent neurodevelopmental disorders due to 
CNS folate deficiency. FR autoantibody screening studies 
should be recommended and validated in the population 
to determine the incidence of FR autoimmunity, health 
risks and strategies for prevention. Similar genetic screen-
ing methods for FOLR-1 mutations can be performed in 
the general population to determine their incidence. In 
addition, parental counseling and testing for FR antibod-
ies before a planned pregnancy should be assessed with 
the goal to reduce the incidence of neural tube defects and 
autism spectrum disorders. Preliminary studies have sug-
gested that even a number of healthy individuals possess 
low FR antibody titers. Our findings of fluctuating FR 
antibodies in CFD syndrome might also be present during 
pregnancy of clinically healthy mothers and represent 
a major issue which can be resolved by repeated serum 
testing. 
 Future studies should also address the association of 
FR autoimmunity with neuro-psychiatric conditions in the 
general population to develop strategies of folate supple-
mentation that could decrease the risk of fetal folate defi-
ciency during pregnancy, postnatal-onset infantile CFD 
and the emergence of CFD syndromes during adolescence 
and adulthood. FR autoimmunity and CFD syndromes 
need to be considered particularly among patients suffer-
ing from unexplained neuropsychiatric conditions (psy-
chomotor retardation, spastic ataxia, dystonia, psychotic 
and schizophrenic syndromes) which appear unrespon-
sive to conventional intervention and drug treatment. 
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